Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

Bellevue Gold Limited operates as a mining company. The Company engages in the exploration and development of gold mines. Bellevue Gold serves customers in Australia.

<ul>
<li>Blue Gold Limited (BGL) has set out to create and distribute the world's first global gold-backed digital currency, the Standard Gold Coin (SGC).</li>
<li>Launch is planned for Q1 2026.</li>
<li>The company intends to support the SGC with its own digital wallet (the One App), with launch planned for Q3 2026.</li>
</ul>


Blue Gold Limited (BGL) has set out to create and distribute the world's first global gold-backed digital currency, the Standard Gold Coin (SGC).
Launch is planned for Q1 2026.
The company intends to support the SGC with its own digital wallet (the One App), with launch planned for Q3 2026.


BGL:  Initiation of a Vertically Integrated Gold Fintech Company...

NewGenIVF Group Ltd. operates as an assisted reproductive services provider. It focuses on providing fertility treatments to fulfil the dreams of building families. The firm offers in-vitro fertilization treatment service, comprising traditional IVF and egg donation, and surrogacy and ancillary caring services. The company was founded by Siu Wing Fung and Fong Hei Yue on January 16, 2019 and is headquartered in Bangkok, Thailand.

<ul><li>Zacks Small-Cap Research Note for NewGenIVF Group Limited (NIVF)</li></ul>

Zacks Small-Cap Research Note for NewGenIVF Group Limited (NIVF)

NIVF: YTD Financial Results Generally Tracking Our 2025 Full-Year Forecasts  Plenty of Growth Catalysts on Tap

NurExone Biologic Inc. operates as a biotech company. The Company develops novel, biologic, and minimal-invasive treatment for spinal cord injury and traumatic brain injury. NurExone Biologic serves customers worldwide.

<ul><li>NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives.</li><li> The technology involved also has the potential to more efficiently get other treatments to the area needed.</li><li> The company announced 3Q results and continues to make tremendous progress in groundbreaking research surrounding the central nervous system and improved drug delivery through exosomes.</li></ul>

NurExone (OTC-NRXBF) is a preclinical stage biotech company that is developing a breakthrough treatment for spinal cord injuries that has the potential to dramatically improve lives. The technology involved also has the potential to more efficiently get other treatments to the area needed. The company announced 3Q results and continues to make tremendous progress in groundbreaking research surrounding the central nervous system and improved drug delivery through exosomes.

NRXBF: Tremendous Progress Made in Groundbreaking Treatment

Arrowhead Pharmaceuticals  / Equity Bottom-Up

Arrowhead Pharmaceuticals, Inc. operates as a biotechnology company. The Company develops medicines that treat intractable diseases by silencing the genes. Arrowhead Pharmaceuticals offers its services in the United States.

<ul><li>On November 25, 2025, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for fiscal year 2026 that ended September 30, 2025.</li><li>Following the recent approval of REDEMPLO , Arrowhead is now a commercial-stage company and has drug in channel only a week following approval, which is ahead of schedule.</li><li>Looking ahead to 2026, Arrowhead has a number of important data readouts, including a first look at obesity data for ARO-INHBE and ARO-ALK7 in January 2026 with a more complete data set expected in mid-2026, interim data for ARO-DIMER-PA in summer 2026, initial ARO-MAPT data looking at tau levels in CSF in summer 2026, topline results from SHASTA-3 and SHASTA-4 in 3Q26 with a potential sNDA filing before the end of 2026, and biomarker data for ARO-RAGE possible by the end of 2026 or in early 2027.</li></ul>

On November 25, 2025, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for fiscal year 2026 that ended September 30, 2025.Following the recent approval of REDEMPLO , Arrowhead is now a commercial-stage company and has drug in channel only a week following approval, which is ahead of schedule.Looking ahead to 2026, Arrowhead has a number of important data readouts, including a first look at obesity data for ARO-INHBE and ARO-ALK7 in January 2026 with a more complete data set expected in mid-2026, interim data for ARO-DIMER-PA in summer 2026, initial ARO-MAPT data looking at tau levels in CSF in summer 2026, topline results from SHASTA-3 and SHASTA-4 in 3Q26 with a potential sNDA filing before the end of 2026, and biomarker data for ARO-RAGE possible by the end of 2026 or in early 2027.

ARWR: Multiple Data Readouts Ahead in 2026 